Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H1710 in Advanced Solid Tumors
NCT06992713Phase 1Recruiting
- Sponsor
- Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of H1710 in solid tumor, sponsored by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Primary endpoints: Incidence and severity of treatment-emergent adverse events at 18 months, Dose Limiting Toxicities at 18 months and 2 more. Started Jun 2025; status: recruiting.
02
Drugs
H1710
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06992713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06992713.